Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
Completed
NRG Oncology
Phase 2
2007-12-17
This phase II trial studies the side effects and how well selumetinib sulfate works in
treating patients with low-grade ovarian cancer that has come back (recurrent). Selumetinib
sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth.
Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
Completed
National Cancer Institute (NCI)
Phase 2
2007-12-17
This phase II trial studies the side effects and how well selumetinib sulfate works in
treating patients with low-grade ovarian cancer that has come back (recurrent). Selumetinib
sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth.
Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
Completed
National Cancer Institute (NCI)
Phase 2
2007-12-01
This phase II trial is studying how well selumetinib works in treating patients with
papillary thyroid cancer that did not respond to radioactive iodine. Selumetinib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
Completed
National Cancer Institute (NCI)
Phase 2
2010-03-01
This phase II trial studies how well selumetinib works in treating patients with multiple
myeloma, a type of cancer in which a specific protein is over active. Selumetinib may stop
the growth of cancer cells by blocking this protein.
Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec
Completed
AstraZeneca
Phase 2
2010-04-01
The purpose of this study is to determine whether treatment with Selumetinib (AZD6244)
(Hyd-Sulfate) in combination with Irinotecan as a second treatment in patients with K-ras or
B-raf mutation will prevent tumor progression and prolong progression free survival.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
